36
Participants
Start Date
April 1, 2022
Primary Completion Date
February 28, 2026
Study Completion Date
April 30, 2026
Ad26.Mos4.HIV
Ad26.Mos4.HIV is a tetravalent vaccine containing Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
MVA-BN-HIV
MVA-BN-HIV is a monovalent vaccine comprising a single Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN®) vector encoding Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
PGT121
PGT121 is a human mAb that targets the HIV-1 V3 glycan, centered on N332.
PGDM1400
PGDM1400 is a human mAb that targets the HIV-1 V2 glycan, centered on N160.
VRC07-523LS
VRC-HIVMAB075-00-AB (VRC07-523LS) is a human monoclonal antibody (mAb) that targets the HIV-1 CD4 binding site.
Orlando Immunology Center, Orlando
University Hospitals Cleveland Medical Center, Cleveland
Washington University Clinical Trials Unit, St Louis
UCLA CARE (Center for AIDs Research and Education), Los Angeles
University of Washington Positive Research, Seattle
Beth Israel Deaconess Medical Center, Boston
Collaborators (1)
Janssen Pharmaceuticals
INDUSTRY
Harvard School of Public Health (HSPH)
OTHER
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Boris Juelg, MD PhD
OTHER